Multiplex PCR in pediatric LRTIs: challenges and opportunities in LMICs
The Journal of Infection in Developing Countries · 2026-10-31 · 20 (10) · 1430-1440
DOI: 10.3855/jidc.22952 ↗Abstract
Introduction: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality among children under five years of age, particularly in low- and middle- income countries (LMICs), where limitations in diagnostic capacity contribute to delayed and suboptimal clinical management. Conventional diagnostic methods are limited by slow turnaround time and reduced sensitivity, especially in mixed infections. This review synthesizes current evidence on the role of multiplex polymerase chain reaction (MxPCR) in the diagnosis and management of pediatric LRTIs, with emphasis on diagnostic accuracy, clinical impact, and implementation considerations in LMIC settings. Methodology: A narrative review of published literature was undertaken, focusing on studies evaluating MxPCR diagnostic performance, clinical outcomes, epidemiological insights, and cost-effectiveness in pediatric respiratory infections, with cross-reference to LMIC specific health system constraints. Observations: MxPCR consistently demonstrates high sensitivity and specificity for the detection of viral, bacterial, and mixed respiratory pathogens, enabling rapid and comprehensive pathogen identification. Evidence indicates improved antibiotic stewardship, reduced unnecessary investigations, and strengthened epidemiological surveillance. However, widespread adoption in LMICs remains limited by high per-test costs, infrastructure requirements, supply chain challenges, and limited local economic evaluation. Conclusions: MxPCR represents a valuable diagnostic advancement for pediatric LRTIs. Sustainable integration in LMICs will require context-specific cost-effectiveness studies, appropriate panel selection based on local epidemiology, and feasible funding. Until these conditions are met, selective use in tertiary or high-dependency pediatric settings, or case-by-case application based on severity, remains the most practical approach.
EUVIMED